<DOC>
	<DOC>NCT01420913</DOC>
	<brief_summary>The purpose of this trial is to compare the pharmacokinetic characteristics of YHD1119 A, YHD1119 B, YHD1119 C and Lyrica capsule. YHD1119 A, B, C are controlled released formulations which are made by YUHAN Corporation. Primary endpoints are C max,ss and AUC tau. Secondary endpoints are AUC last, AUC infinity, T max,ss, t 1/2</brief_summary>
	<brief_title>Randomized, Open-label, Parallel Study to Evaluate the Pharmacokinetic Characteristics of Pregabalin According to Different Controlled Released Formulations in Healthy Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Pregabalin</mesh_term>
	<criteria>20~45 years old, healthy adult male subject &gt;55 Kg(Body weight) and &lt; ideal body weight Â± 20% AST or ALT &gt; 1.25 * Upper normal range (Lab) Total bilirubin &gt; 1.5 * Upper normal range Systolic BP &gt;140 OR &lt;100, Diastolic BP &gt;90 OR &lt;65</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>To evaluate the pharmacokinetic characteristics of Lyrica, YHD1119 A,B,C</keyword>
</DOC>